{"id":"anti-cd22-immunotoxin","safety":{"commonSideEffects":[{"rate":null,"effect":"Vascular leak syndrome"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Immunogenicity/anti-drug antibodies"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Anti-CD22 immunotoxins are fusion proteins combining an anti-CD22 antibody or antibody fragment with a toxin (typically a bacterial or plant-derived toxin like diphtheria toxin or pseudomonas exotoxin). The antibody component targets CD22, a B-cell-restricted antigen, while the toxin moiety is internalized upon binding and inhibits protein synthesis, leading to cell death. This approach aims to selectively eliminate CD22-expressing B-cell malignancies while sparing normal tissues.","oneSentence":"An immunotoxin that binds to CD22 on B-cell lymphomas and delivers a cytotoxic payload to kill malignant cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:55.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell lymphomas (CD22-positive)"},{"name":"Acute lymphoblastic leukemia (ALL, CD22-positive)"}]},"trialDetails":[{"nctId":"NCT03898128","phase":"","title":"ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2019-11-27","conditions":"Acute Lymphoblastic Leukemia","enrollment":84},{"nctId":"NCT00450944","phase":"PHASE1","title":"Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2006-02-22","conditions":"Leukemia","enrollment":10},{"nctId":"NCT03501615","phase":"","title":"An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia","status":"APPROVED_FOR_MARKETING","sponsor":"AstraZeneca","startDate":"","conditions":"Relapsed/Refractory Hairy Cell Leukemia","enrollment":""},{"nctId":"NCT01829711","phase":"PHASE3","title":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-04-29","conditions":"Leukemia, Hairy Cell","enrollment":80},{"nctId":"NCT01408160","phase":"PHASE1","title":"Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-04","conditions":"Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":18},{"nctId":"NCT00889408","phase":"PHASE1","title":"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12-02","conditions":"Leukemia, Lymphoma","enrollment":25},{"nctId":"NCT02338050","phase":"PHASE2","title":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2015-05","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-CD22 Immunotoxin","genericName":"Anti-CD22 Immunotoxin","companyName":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","companyId":"istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-CD22 Immunotoxin is a treatment studied for various conditions, including Acute Lymphoblastic Leukemia, Relapsed/Refractory Hairy Cell Leukemia, and Lymphoma, according to ClinicalTrials.gov. The mechanism of Anti-CD22 Immunotoxin is unknown, as per ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}